NEWS
Meningitis vaccine could reduce
New test for eye cancer in the womb to save sight
A life-saving test that allows doctors to spot a rare form of eye cancer in babies in the womb is being rolled out by the NHS in England. Thanks to a new NHS test developed at Birmingham Women’s and Children’s NHS Foundation Trust, babies identified as being at risk of developing retinoblastoma can be monitored and treated sooner – increasing the chance of saving their eyesight and potentially their lives. Symptoms of retinoblastoma are hard to detect and a diagnosis can normally only be made once the tumour has progressed and the eye can’t be saved.
The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk.
The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100% accuracy if the baby will develop retinoblastoma. Treatment can then start on the affected eye as soon as the baby is born, with doctors closely monitoring the other eye for any signs. The test can also predict if the disease might develop in their siblings and will be offered to families where there is a confirmed case of retinoblastoma in the family. On top of the cutting-edge new test, Birmingham Women’s and Children’s
Hospitals are also developing a non-invasive post-natal cancer test for retinoblastoma patients using eye fluid – which can also identify if a patient is at risk from other cancers later in life. It is hoped that, in the future, this could be eventually done by a simple blood test.
NHS Chief Executive, Amanda Pritchard,
said: “The introduction of this pioneering new test is fantastic news for babies and their parents, and has the potential to save hundreds of lives over the coming years. Cancer is such a terrible illness and a baby being born with it can have a huge impact on parents and families during what should be an incredibly happy time, but backed by world-class innovation and services like the NHS Genomic Medicine Service, through the Long Term Plan, the NHS is developing and delivering more cutting-edge treatments, like this one, to help save lives and keep families together.” Dr. Amy Gerrish, from Birmingham
Women’s and Children’s Trust, said: “The introduction of this technology of cell free DNA analysis will revolutionise the management of all aspects of retinoblastoma from early detection, selection of the best treatments, identification of family members at risk of retinoblastoma, and early detection and treatment of associated adult onset cancers. “We also believe it will help address the huge discrepancy in retinoblastoma outcomes for individuals in high income and low and middle income countries, which has been highlighted by the World Health Organization (WHO).”
10 l
WWW.CLINICALSERVICESJOURNAL.COM
gonorrhoea cases Meningitis vaccines could help improve protection against gonorrhoea amid rising cases globally and increasing bacterial resistance to drugs used to treat the infection, according to findings from three linked papers published in The Lancet Infectious Diseases journal. More than 80 million new cases of gonorrhoea were recorded worldwide in 2020. Declining effectiveness of drug treatments for the bacteria responsible – Neisseria gonorrhoeae – and the lack of a licensed vaccine to prevent the infection have raised concerns about the possibility that gonorrhoea may become more resistant to treatment, or even untreatable. A modelling study led by Professor Peter White, Imperial College London, UK, is the first analysis of the health and economic effects of using a vaccine to protect against gonorrhoea that accounts for its impact on future rates of
infection.The authors recommend vaccinating men-who-have- sex-with-men, at highest risk of gonorrhoea infection, with 4CMenB, which would prevent an estimated 110,000 cases and save £8 million over 10 years.
New patient portal for
Leeds hospital Wellola has been chosen as the preferred bidder by Leeds Teaching Hospitals NHS Trust to deliver its new Patient Portal platform. The new platform will enable the Trust to deliver enhanced patient- facing services, including the ability for patients to view medical records, message care providers, receive vital educational resources, track symptoms and more, supporting the 1.5 million patients that the Trust cares for each year, across all its locations.
The project aims to revolutionise how
the Trust engages with patients, involves them in their healthcare and manages patient interactions.
The platform is an important facilitator of the Trust’s digital vision, enabling the provision of excellent, safe and integrated patient-centred care in Leeds and beyond, and will also support plans to recover elective waiting lists and create virtual wards.
JUNE 2022
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
